Literature DB >> 10948771

Valvular heart disease: assessment of valve morphology and quantification using MR.

J Schwitter1.   

Abstract

For clinical evaluation and decision-making in patients with valvular heart disease, the diagnostic armamentarium expands steadily. This evolution makes it difficult to choose the most appropriate approach for a specific valvular lesion. It may also reflect our uncertainty of what are the findings that best predict clinical outcome of patients, e.g. after surgery. Accordingly, for each type of valvular lesion, some pathopysiological considerations are stated in order to derive the most important measures that would allow optimal guidance of patients. Based on these considerations the value of an MR study is discussed for each valvular lesion. Newest advances in MR technology allow for highly accurate measurements of regurgitant volumes and hence, MR may be the method of choice for a quantitative evaluation of regurgitant valves. For assessment of stenosis severity, measurement of transvalvular pressure gradient is an appropriate measure and MR may not confer benefits over echocardiography, provided the ultrasound window is adequate (and stroke volume is in the normal range). With respect to surgical treatment, valvular morphology is of pivotal importance, particularly for the mitral valve, and echocardiography still appears to be the first line method. Little data relate lesion severity and/or morphology to clinical outcome. Conversely, the extent of cardiac adaptation to pressure- and/or volume-overload, i.e. ventricular remodeling, is a strong predictor of outcome, and is therefore most important for final judgement of the patient. For assessment of left and right ventricular remodeling, echocardiography typically provides all the necessary information. However, in special cases with discrepant findings, with inadequate ultrasound window, or in the preoperative work-up, MR may provide important information regarding cardiac adaptation to valvular lesion.

Entities:  

Mesh:

Year:  2000        PMID: 10948771     DOI: 10.1007/s000590050027

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  7 in total

1.  High temporal resolution phase contrast MRI with multiecho acquisitions.

Authors:  Richard B Thompson; Elliot R McVeigh
Journal:  Magn Reson Med       Date:  2002-03       Impact factor: 4.668

2.  [The use of cross-sectional imaging modalities in the diagnosis of valvular heart disease].

Authors:  M Gutberlet; H Abdul-Khaliq; H Stobbe; M Fröhlich; B Spors; F Knollmann; P Lange; R Hetzer; R Felix
Journal:  Z Kardiol       Date:  2001-12

3.  Evaluation of aortic regurgitation in congenital heart disease: value of MR imaging in comparison to echocardiography.

Authors:  Sebastian Ley; Joachim Eichhorn; Julia Ley-Zaporozhan; Herbert Ulmer; Jens-Peter Schenk; Hans-Ulrich Kauczor; Raoul Arnold
Journal:  Pediatr Radiol       Date:  2007-03-27

4.  Quantification of aortic valve area and left ventricular muscle mass in healthy subjects and patients with symptomatic aortic valve stenosis by MRI.

Authors:  J Haimerl; A Freitag-Krikovic; A Rauch; E Sauer
Journal:  Z Kardiol       Date:  2005-03

5.  Impact of bileaflet mitral valve prolapse on quantification of mitral regurgitation with cardiac magnetic resonance: a single-center study.

Authors:  Gabriella Vincenti; Pier Giorgio Masci; Tobias Rutz; Jonathan De Blois; Milan Prša; Xavier Jeanrenaud; Juerg Schwitter; Pierre Monney
Journal:  J Cardiovasc Magn Reson       Date:  2017-07-27       Impact factor: 5.364

6.  Flow velocity quantification by exploiting the principles of the Doppler effect and magnetic particle imaging.

Authors:  Dennis Pantke; Florian Mueller; Sebastian Reinartz; Fabian Kiessling; Volkmar Schulz
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

Review 7.  Imaging modalities in valvular heart disease.

Authors:  Francisco Aguilar; H Joachim Nesser; Francesco Faletra; Stefano De Castro; Martin Maron; Ayan R Patel; Natesa G Pandian
Journal:  Curr Cardiol Rep       Date:  2008-03       Impact factor: 3.955

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.